Your browser doesn't support javascript.
loading
Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity.
Guo, Yugang; Xie, Yu-Qing; Gao, Min; Zhao, Yang; Franco, Fabien; Wenes, Mathias; Siddiqui, Imran; Bevilacqua, Alessio; Wang, Haiping; Yang, Hanshuo; Feng, Bing; Xie, Xin; Sabatel, Catherine M; Tschumi, Benjamin; Chaiboonchoe, Amphun; Wang, Yuxi; Li, Weimin; Xiao, Weihua; Held, Werner; Romero, Pedro; Ho, Ping-Chih; Tang, Li.
Afiliação
  • Guo Y; Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Xie YQ; Institute of Materials Science & Engineering, EPFL, Lausanne, Switzerland.
  • Gao M; Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Zhao Y; Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Franco F; Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Wenes M; Department of Oncology, University of Lausanne, Epalinges, Switzerland.
  • Siddiqui I; Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.
  • Bevilacqua A; Department of Oncology, University of Lausanne, Epalinges, Switzerland.
  • Wang H; Department of Oncology, University of Lausanne, Epalinges, Switzerland.
  • Yang H; Department of Oncology, University of Lausanne, Epalinges, Switzerland.
  • Feng B; Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.
  • Xie X; Department of Oncology, University of Lausanne, Epalinges, Switzerland.
  • Sabatel CM; Ludwig Institute for Cancer Research, University of Lausanne, Epalinges, Switzerland.
  • Tschumi B; State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University and Collaborative Innovation Center of Biotherapy, Chengdu, China.
  • Chaiboonchoe A; Institute of Bioengineering, École Polytechnique Fédérale de Lausanne (EPFL), Lausanne, Switzerland.
  • Wang Y; Institute of Materials Science & Engineering, EPFL, Lausanne, Switzerland.
  • Li W; Center for Genomics and Systems Biology, New York University Abu Dhabi, Abu Dhabi, United Arab Emirates.
  • Xiao W; Department of Oncology, University of Lausanne, Epalinges, Switzerland.
  • Held W; Department of Oncology, University of Lausanne, Epalinges, Switzerland.
  • Romero P; Siriraj Center of Research Excellence for Systems Pharmacology, Department of Pharmacology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Ho PC; Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China.
  • Tang L; Department of Respiratory and Critical Care Medicine, West China Medical School/West China Hospital, Sichuan University, Chengdu, China.
Nat Immunol ; 22(6): 746-756, 2021 06.
Article em En | MEDLINE | ID: mdl-34031618
ABSTRACT
T cell exhaustion presents one of the major hurdles to cancer immunotherapy. Among exhausted CD8+ tumor-infiltrating lymphocytes, the terminally exhausted subset contributes directly to tumor cell killing owing to its cytotoxic effector function. However, this subset does not respond to immune checkpoint blockades and is difficult to be reinvigorated with restored proliferative capacity. Here, we show that a half-life-extended interleukin-10-Fc fusion protein directly and potently enhanced expansion and effector function of terminally exhausted CD8+ tumor-infiltrating lymphocytes by promoting oxidative phosphorylation, a process that was independent of the progenitor exhausted T cells. Interleukin-10-Fc was a safe and highly efficient metabolic intervention that synergized with adoptive T cell transfer immunotherapy, leading to eradication of established solid tumors and durable cures in the majority of treated mice. These findings show that metabolic reprogramming by upregulating mitochondrial pyruvate carrier-dependent oxidative phosphorylation can revitalize terminally exhausted T cells and enhance the response to cancer immunotherapy.
Assuntos
Imunoterapia Adotiva/métodos; Interleucina-10/farmacologia; Neoplasias/terapia; Fosforilação Oxidativa/efeitos dos fármacos; Linfócitos T Citotóxicos/efeitos dos fármacos; Animais; Proteínas de Transporte de Ânions/genética; Proteínas de Transporte de Ânions/metabolismo; Linhagem Celular Tumoral; Terapia Combinada/métodos; Modelos Animais de Doenças; Sinergismo Farmacológico; Feminino; Células HEK293; Meia-Vida; Humanos; Inibidores de Checkpoint Imunológico/farmacologia; Inibidores de Checkpoint Imunológico/uso terapêutico; Fragmentos Fc das Imunoglobulinas/farmacologia; Fragmentos Fc das Imunoglobulinas/uso terapêutico; Interleucina-10/uso terapêutico; Camundongos; Camundongos Transgênicos; Mitocôndrias/efeitos dos fármacos; Mitocôndrias/metabolismo; Proteínas de Transporte da Membrana Mitocondrial/genética; Proteínas de Transporte da Membrana Mitocondrial/metabolismo; Transportadores de Ácidos Monocarboxílicos/genética; Transportadores de Ácidos Monocarboxílicos/metabolismo; Neoplasias/imunologia; Neoplasias/patologia; Receptores de Antígenos Quiméricos/imunologia; Receptores de Antígenos Quiméricos/metabolismo; Receptores de Interleucina-10/metabolismo; Proteínas Recombinantes de Fusão/farmacologia; Proteínas Recombinantes de Fusão/uso terapêutico; Transdução de Sinais/efeitos dos fármacos; Transdução de Sinais/imunologia; Linfócitos T Citotóxicos/citologia; Linfócitos T Citotóxicos/imunologia; Linfócitos T Citotóxicos/metabolismo

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosforilação Oxidativa / Linfócitos T Citotóxicos / Imunoterapia Adotiva / Interleucina-10 / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fosforilação Oxidativa / Linfócitos T Citotóxicos / Imunoterapia Adotiva / Interleucina-10 / Neoplasias Idioma: En Ano de publicação: 2021 Tipo de documento: Article